New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - cisplatin 1 mg/ml - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml excipient: mannitol sodium chloride water for injection - dbl cisplatin injection is indicated for the palliative treatment of metastatic non-seminomatous germ cell carcinoma, advanced-stage refractory ovarian carcinoma, advanced-stage refractory bladder carcinoma and refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, e.g. radiotherapy or surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cisplatin 1 mg/ml - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml excipient: hydrochloric acid sodium chloride water for injection - cisplatin ebewe is indicated as palliative therapy to be employed as follows: metastatic non-seminomatous germ cell carcinoma: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic non-seminomatous germ cell tumours who have already received appropriate surgical and/or radiotherapeutic procedures. metastatic ovarian tumours: cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy. advanced and refractory carcinoma of the bladder: cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with advanced stage bladder cancer refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy. squamous cell carcinoma of the head and neck (refractory to standard chemotherapy): cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with squamous cell carcinoma of the head and neck refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

biomed limited - noradrenaline acid tartrate monohydrate 0.199 mg/ml equivalent to 0.1 mg/ml noradrenaline base;   - solution for infusion - 0.1 mg/ml - active: noradrenaline acid tartrate monohydrate 0.199 mg/ml equivalent to 0.1 mg/ml noradrenaline base   excipient: glucose sodium metabisulfite water for injection - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion, and drug reactions).

Bangladesh - English - DGDA (Directorate General of Drug Administration)

edcl (dhaka) - adrenaline - injection - 1 mg/ml

Bangladesh - English - DGDA (Directorate General of Drug Administration)

techno drugs ltd. - adrenaline - injection - 1 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

newline pharma, s.l. - articaine hydrochloride; adrenaline tartrate - solution for injection - 40+0.01 milligram(s)/millilitre - articaine, combinations

Bangladesh - English - DGDA (Directorate General of Drug Administration)

gonoshasthaya pharmaceuticals ltd. - adrenaline - injection - 1 mg/ml

Kenya - English - Pharmacy and Poisons Board

adrenaline bitartrate bp equivalent to adrenaline. - injection - 1mg/ml - epinephrine

Kenya - English - Pharmacy and Poisons Board

laboratoire renaudin za errobi 64250 itxassou france - adrenaline inj 1mg/ml 1ml - solution for injection - 1 ml solution for injection contains 1.82mg of… - cardiac stimulants excluding cardiac glycosides:

Kenya - English - Pharmacy and Poisons Board

vital healthcare ltd p.o. box 42718- 00100 gpo nairobi kenya - adrenaline bitartrate bp equivalent to adrenaline. - solution for injection - 1mg/ml - ophthalmological antiglaucoma preparations and